[Pathophysiology of diabetes mellitus type 2 and the mechanism of action and indications for using hypoglycemic sulfonylurea derivatives].
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000503:physiopathology*; D011384:Proinsulin / Q000096:biosynthesis; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D014044:Tolbutamide / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D011384:Proinsulin; D014044:Tolbutamide; D005947:Glucose
Patofizjologia cukrzycy typu II a mechanizm działania i wskazania do stosowania hipoglikemizujacych pochodnych sulfonylomocznika.